Global health care company Abbott (ABT: Quote) Monday announced that its novel XIENCE Xpedition Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease has received CE mark in Europe.
The company stated that the XIENCE Xpedition features a new stent delivery system designed to optimize acute performance, particularly in challenging coronary anatomies. XIENCE Xpedition is supported by the robust clinical evidence of the XIENCE family of stents, including data from more than 45,000 patients across more than 100 studies with long-term outcomes out to five years.
"The extraordinary deliverability of the new XIENCE Xpedition drug eluting stent system allows physicians to treat particularly complex coronary disease with great ease and confidence," said Evald H. Christiansen, M.D., Ph.D., interventional cardiologist, Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, who treated the first patient with XIENCE Xpedition
Abbott further added that it would start to market the new product immediately in all those CE Mark countries.
Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com